News ‘Trojan horse’ cancer drug shows promise in multiple tumour ... A new type of cancer drug that acts as a ‘Trojan horse’ to get inside tumour cells has shown promise in patients with six different cancer types.
News Seattle Genetics and Astellas gain Breakthrough Designation ... The FDA has granted Breakthrough Therapy Designation to enfortumab vedotin, an antibody-drug conjugate (ADC) being developed by Seattle Genetics and Astellas.
Partner Content Partner Content Exclusive Speaker Interview from Seattle Genetics for SMi’s ... Interview from Seattle Genetics
News Seattle, Takeda aim for first line Adcetris use Seattle CEO hopes Adcetris will be standard of care.
News Seattle Genetics halts trials of latest ADC after safety war... Monitoring committee concerned about high death rates.
News Seattle Genetics leukaemia trial on hold after 4 deaths FDA concerned over potential liver toxicity.
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.